2,565 results match your criteria Small Cell Carcinoma of the Bladder


Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.

JCO Precis Oncol 2022 Jun;6:e2100392

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Purpose: To compare oncologic outcomes and genomic alteration profiles in patients with bladder and urachal adenocarcinoma, urothelial carcinoma (UC) with glandular differentiation, and UC, not otherwise specified (NOS) undergoing surgical resection, with emphasis on response to systemic therapy.

Methods: We identified patients with bladder cancer with glandular variants who underwent surgical resection at Memorial Sloan Kettering from 1995 to 2018 (surgical cohort) and/or patients who had tumor sequencing using a targeted next-generation sequencing platform (genomics cohort). Pathologic complete and partial response rates to neoadjuvant chemotherapy (NAC) and recurrence-free and cancer-specific survival were measured. Read More

View Article and Full-Text PDF

NEAT1 variant 1 weakens the genome-wide effect of miR-3122 on blocking H3K79me3 in bladder cancer.

Aging (Albany NY) 2022 Jun 10;14(11):4819-4826. Epub 2022 Jun 10.

Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

Nuclear-enriched abundant transcript 1 (NEAT1) is one of the most well-studied long non-coding RNAs (lncRNAs) in multiple human carcinoma. Two distinct variants of NEAT1, however, are never illuminated their specific functions and mechanisms underlying carcinogenesis. In this study, biotin-labelled NEAT1 variants were generated to incubate with cell lysate of bladder cancer cell T24 cells, and fished a batch of RNA substances. Read More

View Article and Full-Text PDF

Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy.

Clin Genitourin Cancer 2022 May 11. Epub 2022 May 11.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

Introduction: Small cell carcinoma of the bladder (SCCB) is a rare variant of bladder cancer with poor outcomes. We evaluated long-term outcomes of nonmetastatic (M0) and metastatic (M1) SCCB and correlated pathologic response with genomic alterations of patients treated with neoadjuvant chemotherapy (NAC).

Patients And Methods: Clinical history and pathology samples from SCCB patients diagnosed at our institution were reviewed. Read More

View Article and Full-Text PDF

Infection as a Differential Diagnosis of Solid Retroperitoneal Masses: A Case Series and Review of the Literature.

Cureus 2022 May 1;14(5):e24656. Epub 2022 May 1.

Department of Radiology, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, DEU.

The differential diagnosis of retroperitoneal masses includes a variety of benign and malignant conditions, among which infections constitute a significant subgroup. Familiarity with these infectious pseudotumours could facilitate prompt diagnosis. In this report, we describe three patients with an infectious pseudotumour, which was clinically and radiologically highly suggestive of a neoplasm. Read More

View Article and Full-Text PDF

Management about intravesical histological transformation of prostatic mucinous carcinoma after radical prostatectomy: A case report.

World J Clin Cases 2022 May;10(14):4654-4660

Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China.

Background: Prostatic mucinous carcinoma (MC) and prostatic signet ring cell carcinoma are two variants of prostate cancer. MC has a higher overall survival time among all variants, while signet ring cell carcinoma is associated with lower survival time relative to other carcinomas. Only a small proportion of prostatic MC may contain signet ring cells. Read More

View Article and Full-Text PDF

Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes.

Urol Oncol 2022 May 31. Epub 2022 May 31.

Levine Cancer Institute, Atrium Health, Charlotte, NC.

Objectives: Small cell bladder carcinoma (SCBC) represents a rare histologic variant with a poor prognosis and for which no routine biomarkers exist. Limited reports of genomic sequencing in SCBC have demonstrated a high prevalence of TP53 and RB1 gene mutations, though the prognostic value of these and other gene variants in SCBC remains undefined. In this study, we performed targeted genomic sequencing on a cohort of SCBC patients and correlated genomic findings with clinical outcomes to identify potential novel biomarkers. Read More

View Article and Full-Text PDF

Histiocytic Sarcoma with Invasive Urothelial Carcinoma of Urinary Bladder.

J Coll Physicians Surg Pak 2022 Apr;32(4):S79-S81

Department of Pathology, Tekirdag Namik Kemal University, Tekirdag, Turkey.

We report a rare case of histiocytic sarcoma in association with invasive urothelial carcinoma involving the urinary bladder. A 67-year male patient, who presented with a complaint of macroscopic hematuria, was found to have a mass on urinary system ultrasonography. Abdominal magnetic resonance imaging was performed to evaluate the mass, which showed a 52×24 mm mass on the posterior wall of the bladder. Read More

View Article and Full-Text PDF

Synaptophysin, CD117, and GATA3 as a Diagnostic Immunohistochemical Panel for Small Cell Neuroendocrine Carcinoma of the Urinary Tract.

Cancers (Basel) 2022 May 19;14(10). Epub 2022 May 19.

Asan Medical Center, Department of Pathology, University of Ulsan College of Medicine, 88, Olympic-ro 43 Gil, Songpa-gu, Seoul 05505, Korea.

Although SCNEC is based on its characteristic histology, immunohistochemistry (IHC) is commonly employed to confirm neuroendocrine differentiation (NED). The challenge here is that SCNEC may yield negative results for traditional neuroendocrine markers. To establish an IHC panel for NED, 17 neuronal, basal, and luminal markers were examined on a tissue microarray construct generated from 47 cases of 34 patients with SCNEC as a discovery cohort. Read More

View Article and Full-Text PDF

Classifying Pulmonary and Urinary High-grade Neuroendocrine Carcinoma by CK7 Immunohistochemistry.

Appl Immunohistochem Mol Morphol 2022 May 24. Epub 2022 May 24.

University of British Columbia.

High-grade neuroendocrine carcinoma (HGNEC) is subclassified into small cell carcinoma (SmCC) and large cell neuroendocrine carcinoma (LCNEC). Although both are clinically aggressive, the SmCC and LCNEC need to have different treatment strategies, and accurate pathologic diagnosis is challenging. We studied a large retrospective cohort (186 cases) of HGNEC of bladder and lung to investigate the abundance of cytokeratin (CK) 7 expression and staining pattern in SmCC and LCNEC. Read More

View Article and Full-Text PDF

Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer.

Lab Invest 2022 May 17. Epub 2022 May 17.

Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.

Immune checkpoint blockade with programmed cell death (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has resulted in significant progress in the treatment of various cancer types. However, not all patients respond to PD-1/PD-L1 blockade, underscoring the importance of identifying new potential targets for immunotherapy. One promising target is the immune system modulator Siglec-15. Read More

View Article and Full-Text PDF

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.

J Immunother Cancer 2022 05;10(5)

Drug Development Department, Gustave Roussy Institute, Villejuif, France.

Background: This phase 1b study (NCT02323191) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of colony-stimulating factor-1 receptor-blocking monoclonal antibody (mAb) emactuzumab in combination with the programmed cell death-1 ligand (PD-L1)-blocking mAb atezolizumab in patients with advanced solid tumors naïve or experienced for immune checkpoint blockers (ICBs).

Methods: Emactuzumab (500-1350 mg flat) and atezolizumab (1200 mg flat) were administered intravenously every 3 weeks. Dose escalation of emactuzumab was conducted using the 3+3 design up to the maximum tolerated dose (MTD) or optimal biological dose (OBD). Read More

View Article and Full-Text PDF

LINC00958: A promising long non-coding RNA related to cancer.

Biomed Pharmacother 2022 Jul 12;151:113087. Epub 2022 May 12.

Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Key Laboratory of Hepatobiliary and Pancreatic Surgery and Digestive Organ Transplantation of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Open and Key Laboratory of Hepatobiliary & Pancreatic Surgery and Digestive Organ, Transplantation at Henan Universities, Zhengzhou 450052, China; Henan Key Laboratory of Digestive Organ Transplantation, Zhengzhou 450052, China. Electronic address:

Long non-coding RNAs (lncRNAs), a class of RNA transcripts longer than 200 nucleotides, do not encode proteins; however, they encode small peptides and micropeptides that act as bioactive peptides with notable effects in regulating the progression of malignant tumors, such as lung and colorectal cancers, and affecting patient prognosis. lncRNAs are important intracellular regulators, particularly in tumorigenesis and tumor progression. Long intergenic non-protein coding RNA958 (LINC00958), which has received increasing attention in recent years, is highly expressed in various malignancies, including head and neck squamous cell carcinoma (HNSC), non-small-cell lung cancer (NSCLC), gastric cancer, hepatocellular carcinoma (HCC), colorectal cancer, bladder cancer, and breast cancer. Read More

View Article and Full-Text PDF

Budget projections and clinical impact of an immuno-oncology class of treatments: Experience in four EU markets.

J Cancer Policy 2021 06 26;28:100279. Epub 2021 Feb 26.

Vienna Cancer Center (VCC), Vienna Medical University, BT86/E 01, Spitalgasse 23, 1090, Wien, Austria.

Background: Immunotherapies have revolutionized oncology, but their rapid expansion may potentially put healthcare budgets under strain. We developed an approach to reduce demand uncertainty and inform decision makers and payers of the potential health outcomes and budget impact of the anti-PD-1/PD-L1 class of immuno-oncology (IO) treatments.

Methods: We used partitioned survival modelling and budget impact analysis to estimate overall survival, progression-free survival, life years gained (LYG), and number of adverse events (AEs), comparing "worlds with and without" anti-PD-1/PD-L1s over five years. Read More

View Article and Full-Text PDF

A surgical case of high-grade urothelial carcinoma of the renal pelvis complicated with giant hydronephrosis, giving rise to diagnostic difficulties on a cytological examination.

Diagn Pathol 2022 May 11;17(1):47. Epub 2022 May 11.

Kanazawa Medical University Hospital, 1-1, Ishikawa, 920-0293, Uchinada, Japan.

Background: We report a surgical case of urothelial carcinoma of the renal pelvis, resulting in diagnostic difficulties on cytological examination.

Case Presentation: A man in his late 70s underwent nephrectomy for giant hydronephrosis and renal cysts after nephrostomy and renal cyst puncture and drainage. On all cytological examinations performed before surgery, including nephrostomy urine, renal cyst fluid, catheterized bladder urine, and bladder washings, we were unable to make any conclusive diagnosis of malignancy. Read More

View Article and Full-Text PDF

A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers.

Saudi J Biol Sci 2022 Apr 15;29(4):2072-2084. Epub 2022 Jan 15.

Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Najran University, 1988, Najran 61441, Saudi Arabia.

Genitourinary cancers comprise of a heterogenous group of cancers of which renal cell carcinoma, urothelial bladder carcinoma, and prostate adenocarcinoma are the most commonly encountered subtypes. A lot of research is ongoing using various strategies for exploration of novel biomarkers for genitourinary cancers. These biomarkers would not reduce the need for invasive diagnostic techniques but also could be used for early and accurate diagnosis to improve the clinical management required for the disease. Read More

View Article and Full-Text PDF

Association between miR-146a rs2910164, miR-196a2 rs11614913, and miR-499 rs3746444 polymorphisms and the risk of esophageal carcinoma: A case-control study.

Cancer Med 2022 May 2. Epub 2022 May 2.

Department of Cardiothoracic Surgery, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Jiangsu Province, China.

MicroRNAs (miRNAs) are a group of small, non-coding, and endogenous RNAs that regulate gene expression and over 50% of them are located at cancer-related genomic regions or fragile sites. According to previous studies there is significant association of miRNA single nucleotide polymorphisms (SNPs) with tumorigenesis (e.g. Read More

View Article and Full-Text PDF

Recent Advances in Cancer Imaging with CuCl PET/CT.

Authors:
Fangyu Peng

Nucl Med Mol Imaging 2022 Apr 17;56(2):80-85. Epub 2022 Feb 17.

Department of Radiology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9140 USA.

is required for cancer cell proliferation and tumor angiogenesis. Radioactive copper-64 chloride (CuCl) is a useful radiotracer for cancer imaging with position emission tomography (PET) based on increased cellular uptake of copper mediated by human copper transporter 1 (hCtr1) expressed on cancer cell membrane. Significant progress has been made in research of using CuCl as a radiotracer for cancer imaging with PET. Read More

View Article and Full-Text PDF

Transcription factor Fli-1 as a new target for antitumor drug development.

Int J Biol Macromol 2022 Jun 18;209(Pt A):1155-1168. Epub 2022 Apr 18.

State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, P.R. China; The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academic of Science, Guiyang 550014, P.R. China. Electronic address:

The transcription factor Friend leukemia virus integration 1 (Fli-1) belonging to the E26 Transformation-Specific (ETS) transcription factor family is not only expressed in normal cells such as hematopoietic stem cells and vascular endothelial cells, but also abnormally expressed in various malignant tumors including Ewing sarcoma, Merkel cell sarcoma, small cell lung carcinoma, benign or malignant hemangioma, squamous cell carcinoma, adenocarcinoma, bladder cancer, leukemia, and lymphoma. Fli-1 binds to the promoter or enhancer of the target genes and participates in a variety of physiological and pathological processes of tumor cells, including cell growth, proliferation, differentiation, and apoptosis. The expression of Fli-1 gene is related to the specific biological functions and characteristics of the tissue in which it is located. Read More

View Article and Full-Text PDF

TRMT6/61A-dependent base methylation of tRNA-derived fragments regulates gene-silencing activity and the unfolded protein response in bladder cancer.

Nat Commun 2022 04 20;13(1):2165. Epub 2022 Apr 20.

Department of Genetics, University of Alabama, Birmingham, AL, 35233, USA.

RNA modifications are important regulatory elements of RNA functions. However, most genome-wide mapping of RNA modifications has focused on messenger RNAs and transfer RNAs, but such datasets have been lacking for small RNAs. Here we mapped N-methyladenosine (mA) in the cellular small RNA space. Read More

View Article and Full-Text PDF

Intestinal metastasis from carcinoma cervix: An (un) common occurrence in a common cancer. A series of five cases from a single institution.

Indian J Pathol Microbiol 2022 Apr-Jun;65(2):396-400

Department of Pathology, Tata Main Hospital, Jamshedpur, Jharkhand, India.

Carcinoma cervix usually spreads directly to contiguous structures, such as the vagina, urinary bladder, ureter, and rectum. Intestinal metastasis from cervical cancer is very uncommon and accounts for less than 4% of cases and to date, 24 cases have been reported in Medical literature. These may be asymptomatic or present with features of intestinal obstruction, bowel wall perforation, and mimic acute abdomen. Read More

View Article and Full-Text PDF

NUTM1-fusion positive malignant neoplasms of the genitourinary tract: A report of six cases highlighting involvement of unusual anatomic locations and histologic heterogeneity.

Genes Chromosomes Cancer 2022 Apr 17. Epub 2022 Apr 17.

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Tumors with NUTM1 fusions occur predominantly in the thoracic cavity and head and neck region. However, recent literature expanded the location of NUTM1-translocated malignancy to soft tissue, brain, and visceral organs. In this study, we describe the first series of six NUTM1-translocated carcinomas and sarcomas occurring in the genitourinary tract. Read More

View Article and Full-Text PDF

Small cell carcinoma of the urinary bladder: Distinctive cytological characteristics and Cyto-histologic correlation.

Ann Diagn Pathol 2022 Aug 9;59:151947. Epub 2022 Apr 9.

Medical College of Wisconsin, Pathology Department, Milwaukee, WI, USA. Electronic address:

Preoperative diagnosis in liquid-based cytology preparation in voided urine specimen and cyto-histologic correlation of small cell carcinoma of the urinary bladder has not been described in detail in the literature. A 79-year old male presented at our institution with gross hematuria. He was accurately diagnosed with small cell carcinoma of the bladder on liquid-based cytology in urine. Read More

View Article and Full-Text PDF

Cruciferous vegetable consumption and multiple health outcomes: an umbrella review of 41 systematic reviews and meta-analyses of 303 observational studies.

Food Funct 2022 Apr 20;13(8):4247-4259. Epub 2022 Apr 20.

Department of Clinical Epidemiology, Clinical Research Center, Shengjing Hospital of China Medical University, No. 36, San Hao Street, Shenyang, Liaoning 110004, P. R. China.

: Epidemiological studies evaluating the associations between the consumption of cruciferous vegetables (CV) and diverse health outcomes have generated inconsistent findings. Therefore, we carried out an umbrella review to systematically summarize existing evidence on this topic. : This study had been registered at PROSPERO (no. Read More

View Article and Full-Text PDF

BK virus associated with small cell carcinoma of bladder in a patient with renal transplant.

BMJ Case Rep 2022 Mar 29;15(3). Epub 2022 Mar 29.

Division of Infectious Diseases, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA

A man in his 70s with a complex medical history, including cadaveric renal transplant, presented with recurrent urinary tract infections. Investigation revealed recurrent urinary pathogens, including and persistent BK viruria. Cystoscopy revealed a pedunculated mass in the right posterior-lateral wall, inferior to the transplant urethral orifice, and biopsy of this mass showed invasive small cell carcinoma with a prominent adenocarcinoma component. Read More

View Article and Full-Text PDF

Preliminary Evaluation of Ga-P16-093, a PET Radiotracer Targeting Prostate-Specific Membrane Antigen in Prostate Cancer.

Mol Imaging Biol 2022 Mar 29. Epub 2022 Mar 29.

Department of Radiology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce Street, Philadelphia, PA, 19104, USA.

Purpose: Prostate-specific membrane antigen (PSMA) is a promising molecular target for imaging of prostate adenocarcinoma. Ga-P16-093, a small molecule PSMA ligand, previously showed equivalent diagnostic performance compared to Ga-PSMA-11 PET/CT in a pilot study of prostate cancer patients with biochemical recurrence (BCR). We performed a pilot study for further characterization of Ga-P16-093 including comparison to conventional imaging. Read More

View Article and Full-Text PDF

Recent Development of Prodrugs of Gemcitabine.

Genes (Basel) 2022 03 5;13(3). Epub 2022 Mar 5.

Department of Chemistry, University at Albany, 1400 Washington Ave., Albany, NY 12222, USA.

Gemcitabine is a nucleoside analog that has been used widely as an anticancer drug for the treatment of a variety of conditions, including ovarian, bladder, non-small-cell lung, pancreatic, and breast cancer. However, enzymatic deamination, fast systemic clearance, and the emergence of chemoresistance have limited its efficacy. Different prodrug strategies have been explored in recent years, seeking to obtain better pharmacokinetic properties, efficacy, and safety. Read More

View Article and Full-Text PDF

Molecular Markers in Urinary Bladder Cancer: Applications for Diagnosis, Prognosis and Therapy.

Vet Sci 2022 Feb 28;9(3). Epub 2022 Feb 28.

Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), Inov4Agro, University of Trás-os-Montes e Alto Douro (UTAD), Quinta de Prados, 5000-801 Vila Real, Portugal.

Cancer of the urinary bladder is a neoplasm with considerable importance in veterinary medicine, given its high incidence in several domestic animal species and its life-threatening character. Bladder cancer in companion animals shows a complex and still poorly understood biopathology, and this lack of knowledge has limited therapeutic progress over the years. Even so, important advances concerning the identification of tumour markers with clinical applications at the diagnosis, prognosis and therapeutic levels have recently been made, for example, the identification of pathological mutations. Read More

View Article and Full-Text PDF
February 2022

Synthesis and biological evaluation of Al[F]-NOTA-IPB-PDL1P as a molecular probe for PET imaging of PD-L1 positive tumors.

Bioorg Chem 2022 05 26;122:105682. Epub 2022 Feb 26.

GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangdong Province, China; Department of Nuclear Medicine, Shenzhen Hospital, Peking University, Shenzhen, Guangdong Province, China. Electronic address:

PD-L1 is widely expressed in a variety of tumors, including NSCLC, melanoma, renal cell carcinoma, gastric cancer, hepatocellular as well as cutaneous and various leukemias, multiple myeloma and so on. Herein, we designed a novel peptide imaging agent (Al[F]-NOTA-IPB-PDL1P) that specifically targets PD-L1 expressed in tumors. The overall radiochemical yield of Al[F]-NOTA-IPB-PDL1P from F was 10-15% (corrected radiochemical yield) within 20 min and the radiochemical purity of Al[F]-NOTA-IPB-PDL1P was > 95% with a molar activity of 44. Read More

View Article and Full-Text PDF